靶向B7H3的通用型CAR-T细胞及其制备方法和应用

By preparing universal CAR-T cells targeting B7H3 and knocking out the TCR and HLA-A genes using CRISPR/Cas9, the difficulties in expansion and immune rejection in CAR-T cell therapy for glioblastoma were resolved, improving the therapeutic effect and cell survival time.

CN117986362BActive Publication Date: 2026-07-17YANTAI MAOXING BIOTECHNOLOGY CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
YANTAI MAOXING BIOTECHNOLOGY CO LTD
Filing Date
2023-11-03
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

In current CAR-T cell therapy for glioblastoma, it is difficult to expand the patient's own T cells, universal CAR-T cells have problems with graft-versus-host disease and immune rejection, and the overexpression of B7-H3 protein in tumor cells leads to limited side effects.

Method used

We prepared universal CAR-T cells targeting two epitopes of the B7H3 protein. By knocking out the TCR and HLA-A genes using the CRISPR/Cas9 system, the cells could bind to the B7H3-specific antigen, reducing immune rejection and prolonging cell survival time.

Benefits of technology

It improved the anti-tumor effect, reduced the immune rejection response caused by allogeneic CAR-T therapy, and enhanced the anti-tumor activity and survival ability of CAR-T cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004531644280000471
    Figure BDA0004531644280000471
  • Figure BDA0004531644280000472
    Figure BDA0004531644280000472
  • Figure BDA0004531644280000481
    Figure BDA0004531644280000481
Patent Text Reader

Abstract

本申请涉及一种B7H3结合多肽，其包含两个不同抗B7H3单域抗体。本申请还涉及包含所述B7H3结合多肽的嵌合抗原受体，以及包含所述嵌合抗原受体的通用型CAR‑T细胞，识别肿瘤细胞表面抗原的同时，敲除细胞表达的TCR和HLA‑A基因，从而降低异体CAR‑T治疗引起的免疫排斥反应，延长细胞存活时间，提高抗肿瘤效果。
Need to check novelty before this filing date? Find Prior Art